NDRA - エンドラ・ライフ・サイエンシズ (ENDRA Life Sciences Inc.) エンドラ・ライフ・サイエンシズ

 NDRAのチャート


 NDRAの企業情報

symbol NDRA
会社名 ENDRA Life Sciences Inc (エンドラ・ライフ・サイエンシズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ENDRA Life Sciences Inc. is engaged in commercialization of an enhanced ultrasound technology for the pre-clinical research market. The Company's Nexus 128 system combines light-based thermoacoustics and ultrasound to address the imaging needs of researchers studying disease models in pre-clinical applications. The Company is involved in developing TAEUS for incorporation into new ultrasound systems. The TAEUS platform has capabilities and potential clinical applications such as enabling ultrasound to distinguish fat from lean tissue; enabling traditional ultrasound to visualize changes in tissue temperature in real time; enabling ultrasound to view blood vessels from any angle using only a saline solution contrasting agent unlike Doppler ultrasound which requires precise viewing angles and enabling ultrasound to image blood flow at the capillary level in a region organ or tissue.   エンドラ・ライフ・サイエンシズは米国の医療機器メ―カ―。主に超音波技術の開発に従事する。同社の「Nexus 128」は、光音響画像と超音波を組み合わせた3D断層撮影装置で、臨床前研究において使用される。また、開発中の「TAEUS」は、熱音響を利用した超音波システムで、さまざまな病状の診断や治療に活用できる。本社はミシガン州アナ―バ―。   
本社所在地 3600 Green Court Suite 350 Ann Arbor MI 48105-1570 USA
代表者氏名 Francois Michelon フランソワミッシェロン
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 734-335-0468
設立年月日 39264
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数 13人
url www.endrainc.com
nasdaq_url https://www.nasdaq.com/symbol/ndra
adr_tso
EBITDA EBITDA(百万ドル) -7.80746
終値(lastsale) 2.8694
時価総額(marketcap) 11256733.6738
時価総額 時価総額(百万ドル) 11.06294
売上高 売上高(百万ドル) 0.30002
企業価値(EV) 企業価値(EV)(百万ドル) 9.21066
当期純利益 当期純利益(百万ドル) -7.87562
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ENDRA Life Sciences Inc revenues decreased 89% to $6K. Net loss increased from $2.2M to $4.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $271K to $2.5M (expense) Selling/General/Admin. Expense increase of 75% to $2M (expense).

 NDRAのテクニカル分析


 NDRAのニュース

   ENDRA Life Sciences to Present at AIUM Annual Integrative Ultrasound Meeting  2021/04/08 12:30:00 Yahoo Finance
ANN ARBOR, MI / ACCESSWIRE / April 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the Company's Chief Technology Officer will be making a presentation at the American Institute of Ultrasound in Medicine (AIUM) Annual Integrative Ultrasound Meeting on April 14 at 11:45 am ET.
   The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs  2021/03/19 11:46:46 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Vericel Corporation (NASDAQ: VCEL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 18) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) (issued a corporate update) Galecto, Inc. (NASDAQ: GLTO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus Sarepta Presents Positive Data For Gene Therapy to Treat Limb-gridle Muscular Dystrophy Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) announced new results from the ongoing study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E, showing sustained protein expression in muscle tissue.
   ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials  2021/03/18 08:01:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   ENDRA Life Sciences Announces New Clinical Study Partnership with Inselspital University Hospital in Bern, Switzerland  2021/02/17 13:00:00 Yahoo Finance
Study to Bolster Clinical Performance Evidence of TAEUS® Ultrasound Device in NAFLD Patients as Commercialization BeginsANN ARBOR, MI / ACCESSWIRE / February 17, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound .
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   ENDRA Life Sciences to Present at AIUM Annual Integrative Ultrasound Meeting  2021/04/08 12:30:00 Yahoo Finance
ANN ARBOR, MI / ACCESSWIRE / April 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the Company's Chief Technology Officer will be making a presentation at the American Institute of Ultrasound in Medicine (AIUM) Annual Integrative Ultrasound Meeting on April 14 at 11:45 am ET.
   The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs  2021/03/19 11:46:46 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 18) AngioDynamics, Inc. (NASDAQ: ANGO ) Anixa Biosciences, Inc. (NASDAQ: ANIX ) ENDRA Life Sciences Inc. (NASDAQ: NDRA ) (announced a collaboration with Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA ) for NASH studies) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Neos Therapeutics, Inc. (NASDAQ: NEOS ) (reacted to the shareholder meeting held to vote on the proposal to merge with Aytu BioScience, Inc. (NASDAQ: AYTU )) NuVasive, Inc. (NASDAQ: NUVA ) SI-BONE, Inc. (NASDAQ: SIBN ) Sierra Oncology, Inc. (NASDAQ: SRRA ) Silverback Therapeutics, Inc. (NASDAQ: SBTX ) Terns Pharmaceuticals, Inc. (NASDAQ: TERN ) Varian Medical Systems, Inc. (NASDAQ: VAR ) Vericel Corporation (NASDAQ: VCEL ) Vincerx Pharma, Inc. (NASDAQ: VINC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 18) Foghorn Therapeutics Inc. (NASDAQ: FHTX ) (issued a corporate update) Galecto, Inc. (NASDAQ: GLTO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus Sarepta Presents Positive Data For Gene Therapy to Treat Limb-gridle Muscular Dystrophy Sarepta Therapeutics, Inc. (NASDAQ: SRPT ) announced new results from the ongoing study of SRP-9003, its investigational gene therapy for limb-girdle muscular dystrophy Type 2E, showing sustained protein expression in muscle tissue.
   ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials  2021/03/18 08:01:00 Benzinga
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of …
   ENDRA Life Sciences Announces New Clinical Study Partnership with Inselspital University Hospital in Bern, Switzerland  2021/02/17 13:00:00 Yahoo Finance
Study to Bolster Clinical Performance Evidence of TAEUS® Ultrasound Device in NAFLD Patients as Commercialization BeginsANN ARBOR, MI / ACCESSWIRE / February 17, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of enhanced ultrasound .
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.
   ENDRA Life Sciences Granted 13th U.S. Patent for its TAEUS(R) Platform Technology  2021/01/13 14:00:00 Yahoo Finance
Now Has 78 Patents Issued, Filed, Licensed or in Preparation As Taeus® Commercial Launch Plans AdvanceANN ARBOR, MI / ACCESSWIRE / January 13, 2021 /ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has recently been issued United States Patent 10888898 (the '898 patent) entitled "Shielded Ultrasound Transducer and Imaging System Employing the Same" from the United States Patent and Trademark Office.
   ENDRA Life Sciences Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option - Stocks News Feed  2020/12/18 17:39:27 Stocks News Feed
ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today reported the closing of its previously announced underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per share. In connection with the offering, the underwriter exercised… Read More »ENDRA Life Sciences Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option
   ENDRA Life Sciences Announces Pricing of Public Offering of Common Stock - Stocks News Feed  2020/12/16 05:39:01 Stocks News Feed
ANN ARBOR, MI / ACCESSWIRE / December 15, 2020 / ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ:NDRA), a developer of enhanced ultrasound technologies, today announced the pricing of an underwritten public offering of 7,143,000 shares of common stock at an offering price of $0.70 per Common Share. In addition, ENDRA has granted the underwriter a 45-day… Read More »ENDRA Life Sciences Announces Pricing of Public Offering of Common Stock

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エンドラ・ライフ・サイエンシズ NDRA ENDRA Life Sciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)